• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott nabs U.K. reimbursement win for FreeStyle Libre CGM

September 13, 2017 By Sarah Faulkner

AbbottAbbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitoring system will be available for reimbursement in the U.K., starting on Nov. 1.

The company’s system is designed to automatically read glucose levels through a sensor that’s worn on the back of a person’s upper arm for up to 14 days, thereby eliminating routine finger sticks.

Users can track their glucose levels and trends over time using the system’s Ambulatory Glucose Profile, Abbott said. The CGM tech can also help doctors make more informed treatment decisions, according to the company.

“The FreeStyle Libre system has been shown to offer life-changing improvements for people with diabetes to help them live healthier and fuller lives,” Neil Harris, GM of Abbott’s UK diabetes care business, said in prepared remarks. “We are delighted with the NHS decision, and we look forward to partnering with them to provide people with diabetes our innovative technology to help manage their condition.”

“FreeStyle Libre has allowed me to properly track my glucose – it’s finally connected the dots when it comes to managing my diabetes,” Dave Sowerby, a 42-year old living with Type I diabetes in Lancashire, U.K., added. “FreeStyle Libre more easily allows you to track how your glucose is changing versus using the finger stick method, as you can just scan on the go. This decision will allow people to finally take control of their condition, and understand it in a way they’ve never been able to before.”

The company touted real-world data from 50,000 users that show that people with diabetes who use the FreeStyle Libre system measure their glucose levels, on average, 15 times each day. There is also research demonstrating that people who frequently measure their blood glucose levels spend less time in hypoglycemia or hyperglycemia, demonstrating improved glucose control overall, the company reported.

With this reimbursement win, the U.K. joins a group of 17 countries that partially or fully reimburse for Abbott’s FreeStyle Libre, including France, Germany and Japan.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Featured, Patient Monitoring, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS